Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).

Full DD Report for IOVA

You must become a subscriber to view this report.


Recent News from (NASDAQ: IOVA)

Today's Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics
NEW YORK, NY / ACCESSWIRE / September 7, 2018 / Arrowhead Pharmaceuticals exploded on positive data results on Thursday while shares of Iovance Biotherapeutics were deep in the red on its own concerning clinical update. RDI Initiates Coverage on: Arrowhead Pharmaceuticals, Inc. htt...
Source: ACCESSWIRE IA
Date: September, 07 2018 08:00
Midday Gainers / Losers (09/06/2018)
Gainers: ARWR +45% . WSCI +34% . CVM +28% . ABAC +24% . CLDR +23% . SDPI +22% . NBEV +17% . SUPV +17% . AVAV +17% . IMMP +15% . More news on: Arrowhead Pharmaceuticals, WSI Industries Inc., Cel-Sci Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 06 2018 13:03
Premarket Losers as of 9:05 am (9/6/2018)
LE   -15%  on Q2 earnings . More news on: Lands' End, Inc., Iovance Biotherapeutics, Inc., Barnes & Noble Inc, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 06 2018 09:12
Iovance Bio down 12% premarket following corporate presentation
Iovance Biotherapeutics (NASDAQ: IOVA ) slumps  12%  premarket on increased volume on the heels of a presentation at the H.C. Wainwright Global Investor Conference in New York City yesterday. More news on: Iovance Biotherapeutics, Inc., Bristol-Myers Squibb Company, Healthcare st...
Source: SeekingAlpha
Date: September, 06 2018 08:39
Iovance Biotherapeutics to Present at Two Investor Conferences in September
SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two invest...
Source: GlobeNewswire
Date: August, 29 2018 08:01
Iovance updates on TIL collaborations
Iovance Therapeutics (NASDAQ: IOVA ) announces updates to its collaborations investigating the use of tumor-infiltrating lymphocytes (TIL) in a range of cancers. More news on: Iovance Biotherapeutics, Inc., Bristol-Myers Squibb Company, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 16 2018 09:10
Iovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center
- First Patient Dosed with LN-145 in Phase 2 Trial with MD Anderson for Treatment of Sarcomas and Ovarian Cancer - - Preliminary Data from Moffitt NSCLC Study to be Presented at the Upcoming 19th World Conference on Lung Cancer in September 2018 - SAN CARLOS, Calif., Aug. 16, 2018 (...
Source: GlobeNewswire
Date: August, 16 2018 08:01
Iovance Biotherapeutics: Compelling Bet In Metastatic Melanoma
Let The Records Play It's difficult for a popular thing of the past to make a comeback, but we've seen it before (vinyl records). Perhaps, there's room for immuno-oncology, or IO?. Once the new kid on the block, IO has since taken a backseat on the biotech bus to technologies like CRISPR. Gr...
Source: SeekingAlpha
Date: August, 14 2018 04:07
Iovance Biotherapeutics' (IOVA) CEO Maria Fardis on Q2 2018 Results - Earnings Call Transcript
Iovance Biotherapeutics, Inc. (IOVA) Q2 2018 Earnings Conference Call August 6, 2018 4:30 PM ET Executives Tim Morris – Chief Financial Officer Maria Fardis – President and Chief Executive Officer Analysts Boris Peaker – Cowen Mark Breidenbach – ...
Source: SeekingAlpha
Date: August, 06 2018 21:35
Iovance Bio ended Q2 with $276.1M in cash; shares down 1% after hours
Iovance Biotherapeutics (NASDAQ: IOVA ) announces that it ended Q2 with $276.1M in cash. Net loss for the quarter was $30.7M. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: August, 06 2018 16:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0812.7012.6513.3012.251,736,646
2018-05-1716.6016.3517.0016.10802,846

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14178,773350,88650.9490Short
2018-12-1383,399135,40461.5927Short
2018-12-1277,244137,05356.3607Short
2018-12-11103,809154,95666.9926Short
2018-12-10195,757363,12153.9096Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IOVA.


About Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

Logo for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

Not available

 

Contact Information

 

 

Current Management

  • Manish Singh / CEO
  • Merrill A. McPeak / Interim CEO
  • Elma Hawkins / COO
  • Michael Handelman / CFO
  • Jay Venkatesan / Chairman
  • Sanford Hillsberg /
  • Ryan D. Maynard /
  • Merrill A. McPeak /

Current Share Structure

  • Market Cap: $1,359,575,446 - 05/11/2018
  • Issue and Outstanding: 89,445,753 - 02/28/2018

 


Recent Filings from (NASDAQ: IOVA)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: IOVA)

Daily Technical Chart for (NASDAQ: IOVA)


Stay tuned for daily updates and more on (NASDAQ: IOVA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IOVA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IOVA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IOVA and does not buy, sell, or trade any shares of IOVA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/